UNIVERSITY OF BIRMINGHAM

University of Birmingham Research at Birmingham

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19

Mao, Ren; Qiu, Yun; He, Jin-Shen; Tan, Jin-Yu; Li, Xue-Hua; Liang, Jie; Shen, Jun; Zhu, Liang-Ru; Chen, Yan; Iacucci, Marietta; Ng, Siew C; Ghosh, Subrata; Chen, Min-Hu

[Link to publication on Research at Birmingham portal](#)

1 **Manifestations and Prognosis of Gastrointestinal and Liver Involvement in**

2 **Patients with COVID-19: a Rapid Systematic Review and Meta-analysis**

3

4 **Short Title: Gastrointestinal and Liver Involvement in COVID-19**

5

6 Ren Mao，MD[1*], Yun Qiu，MD[1*], Jin-Shen He，MD[1*], Jin-Yu Tan，MD[1*], Xue-Hua

7 Li，MD[2*], Prof. Jie Liang，MD[3], Jun Shen，MD[4], Prof. Liang-Ru Zhu，MD[5], Prof.

8 Yan Chen，MD[6], Marietta Iacucci，MD[7], Prof. Siew C Ng，MD[8], Prof. Subrata Ghosh，

9 MD[7], and Prof. Min-Hu Chen，MD[1]

10

11 [*]These authors contributed equally.

12

13 [1]Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen

14 University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China.

15 [2]Department of Radiology, The First Affiliated Hospital of Sun Yat-sen University, 58

16 Zhongshan II Road, Guangzhou, 510080, People's Republic of China.

17 [3]State key Laboratory of Cancer Biology, National Clinical Research Center for

18 Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Medical

19 University, Xi'an, 710032, People's Republic of China.

20 [4]Division of Gastroenterology and Hepatology, Ren Ji Hospital, School of Medicine,

21 Shanghai Jiao Tong University, Shanghai Cancer Institute, Shanghai Institute of

1   Digestive Disease, Shanghai Inflammatory Bowel Disease Research Center, Shanghai,

2   160 Pu Jian Ave, Shanghai 200127, People's Republic of China.

3   [5]Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong

4   University of Science and Technology, Wuhan, People's Republic of China.

5   [6]Yan Chen , Center for Inflammatory Bowel Diseases, Department of Gastroenterology,

6   the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

7   310009, China.

8   [7]NIHR Biomedical Research Institute, Institute of Translational Medicine, University

9   of Birmingham and University Hospitals Birmingham NHS Foundation Trust, United

10   Kingdom.

11   [8]Department of Medicine and Therapeutics, The Chinese University of Hong Kong,

12   New Territories, Hong Kong. Institute of Digestive Disease, State Key Laboratory of

13   Digestive Diseases, LKS Institute of Health Science, The Chinese University of Hong

14   Kong, New Territories, Hong Kong

15

16   **Corresponding author:**

17   Prof. Min-Hu Chen and Prof. Ren Mao, Department of Gastroenterology, The First

18   Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou,

19   510080, People's Republic of China (e-mail: chenminhu@mail.sysu.edu.cn;

20   maoren2023@gmail.com).

21

1 **Conflict of interest :**

2 All authors declared no conflict of interest

3 **Grant support:** None

4

5 **Author contributions:**

6 R Mao and MH Chen conceived the study. S Ghosh, MH Chen, S Ng supervised the

7 overall study. R Mao and Y Qiu wrote the manuscript. R Mao, Y Qiu, JS He, JY Tan

8 and XH Li analyzed the data. J Shen, J Liang, LR Zhu, Y Chen and M Iacucci critically

9 revised the manuscript.

10

11 **Research in context**

12 **Evidence before this study**

13 The emergence and spread of COVID-19 has brought great challenges to global public

14 health. There are increasing number of studies reporting the gastrointestinal (GI)

15 symptom and liver injury in patients with COVID-19, and severe patients tend to have

16 a higher risk of developing GI symptoms and abnormal liver function. However, results

17 were inconsistent with remarkable heterogeneity among studies and the exact

18 magnitude of GI and liver involvement remains uncertain. Study providing detailed

19 pooled estimates of incidence of gastrointestinal and liver involvement in COVID-19

20 is needed. Whether this unique group of patients has a poor disease course remains

21 unclarified.

Added value of this study

We searched the PubMed, Embase, Web of Science，WHO database of publications, the Lancet COVID-19 Resource Centre, NEJM, JAMA, BMJ, Gastroenterology, GUT, American Journal of Gastroenterology, and Centers for Disease Control and Prevention (CDC) COVID-19 publications. We present pooled estimate rate of GI symptom and liver injury in COVID-19. Furthermore, we present the subgroup analysis of severe vs non-severe cases, patients in Hubei province vs outside Hubei, and paediatric vs adult patients. Features of patients with pre-existing digestive diseases and initially presenting with GI symptoms were summarized.   The disease course of patients with digestive system involvement was further analysed.

Implications of all the available evidence

Digestive symptom and liver injury are not uncommon in patients with COVID-19. Compared with non-severe cases, severe cases with COVID-19 had a higher risk of developing GI symptoms and liver injury. Paediatric patients have equivalent prevalence of presenting with GI symptoms compared to adult patients. Patients in Hubei had higher rate of abnormal liver functions compared to those outside Hubei. One tenth of patients with COVID-19 may present only with GI symptoms without respiratory symptoms. Patients with digestive system involvement have delayed diagnosis with a tendency to progress to severe/critical type and a poor disease course.

1 **Summary**

2 **BACKGROUND:** The prevalence and prognosis of digestive system involvement

3 including gastrointestinal symptoms and liver injury in patients with COVID-19

4 remains largely underappreciated. Here we performed a meta-analysis to quantify the

5 effects of COVID-19 on digestive system.

6 **METHODS**: We systematically searched databases for studies reporting digestive

7 system symptoms in COVID-19 patients up to April 4, 2020. Raw data from studies

8 were pooled to determine effect estimates.

9 **FINDINGS:** We analyzed findings from 35 studies including 6,686 COVID-19

10 patients that met inclusion criteria. The pooled estimate of digestive system

11 comorbidities rate was 4% (95% CI: 2%- 5%; range: 0%–15%; I^2=74%). The pooled

12 rate of digestive symptoms was 15% (95% CI: 10%- 21%; range: 2%–57%; I^2= 96%)

13 with nausea and/or vomiting, diarrhoea and loss of appetite being the three most

14 common ones. The pooled estimate of abnormal liver functions was 19% (95% CI: 9%-

15 32%; range: 1%-53%; I^2= 96%). Subgroup analysis showed patients with severe cases

16 had higher rate of GI symptoms (OR1.61, 95% CI: 1.26-2.06, p=0.0040, I^2=35%) and

17 liver injury (OR 2.2, 95% CI: 1.60-3.02, p<0.001, I^2=36%,) compared to non-severe

18 cases. Patients in Hubei province where the COVID-19 initial outbreak happened in

19 China are more likely to present with abnormal liver functions (all < 0.01) compared

20 with those outside Hubei. Paediatric patients have similar prevalence of GI symptoms

21 compared to adult patients. About 10% (95% CI: 4%- 19%; range: 3%–23%; I^2= 97%)

1   patients presented with GI symptoms alone without respiratory features. Patients with

2   GI system involvement tend to have delayed diagnosis (SMD 2.85, 95% CI: 0.22-5.48,

3   p=0.030, I^2=73%) and poor disease course.

4

5   **INTERPRETATIONS:** Our study showed that digestive symptom and liver injury are

6   not uncommon in patients with COVID-19. Compared with non-severe cases, severe

7   cases with COVID-19 had a higher risk of developing GI symptoms and liver injury.

8   Paediatric patients with COVID-19 have equivalent risk of GI symptoms compared

9   with adult patients. One tenth of patients with COVID-19 may present only with GI

10   symptoms without respiratory symptoms. Patients with digestive system involvement

11   have delayed diagnosis with a tendency to have a poor disease course.

12

13   **FUNDINGS:** None

14

1 **Introduction**

2 The outbreak of coronavirus disease 2019 (COVID-19) has been tremendously

3 impacting the entire world since December 2019. As of April 3rd, 2020, more than 900

4 000 laboratory-confirmed cases and more than 50 000 deaths in over 100 countries had

5 been reported. [1]

6 Respiratory tract manifestations such as fever and cough are the most common reported

7 symptoms in patients with COVID-19.[2] The evidence of digestive system involvement

8 in COVID-19 was first reported by a group in China.[3] Emerging data showed that the

9 gastrointestinal (GI) tract and liver might also represent target organs of Severe Acute

10 Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), based on the findings that cell

11 receptor angiotensin converting enzyme II (ACE2), the major receptor of SARS-CoV-

12 2, is expressed in GI tract as well as liver cells.[4] More importantly, the evidence of

13 SARS-CoV-2 detection in patients' stool and the potential faecal-oral route transmission

14 have raised great concern and posed a challenge for control and prevention of COVID-

15 19.[5-7]

16 There are increasing number of studies reporting the GI symptom and liver injury in

17 patients with COVID-19, and severe patients tend to have a higher risk of developing

18 GI symptoms and abnormal liver function.[2] However, results were inconsistent with

19 remarkable heterogeneity among studies and the exact magnitude of GI and liver

20 involvement remains uncertain. Compared to adult patients, paediatric patients seem to

1   have clinically milder symptoms and showed less alterations in radiological and

2   laboratory testing parameters.[8] Whether paediatric patients had lower risk of GI and liver

3   involvement remains unclear. Moreover, several studies have provided information on

4   the epidemiology and clinical manifestation of the disease outside Hubei province.

5   Whether the GI manifestation and liver injury in disease in Hubei differs from that

6   outside Hubei has seldom been evaluated.[9, 10]

7   More importantly, the prognosis of COVID-19 patients with GI symptoms is still largely

8   unknown. Recent studies[11, 12] implied that COVID-19 patients with digestive symptoms

9   may have a worse clinical outcome compared to those without digestive symptoms,

10   emphasizing the importance of including symptoms such as diarrhoea to diagnose

11   COVID-19 early. As demonstrated by a recent study, the rate of the severe/critical type

12   was also markedly increased in COVID-19 patients with GI symptoms than in those

13   without GI symptoms. Moreover, COVID-19 patients with GI symptoms had

14   significantly higher complications of acute respiratory distress syndrome (ARDS) and

15   liver injury than those without these symptoms.[11] Pan et al[12] also showed that as the

16   severity of the disease increased, digestive symptoms became more pronounced.

17   We performed a systematic review and meta-analysis of current emerging studies

18   reporting GI symptoms and liver injury in patients with COVID-19 based on different

19   disease severity, age groups and geographical regions. We also explored the disease

20   course of this subgroup of patients with GI symptoms. We aimed to update the

21   information with high evidence level and provide insights into the epidemiology of

1   digestive system involvement in COVID-19 as an urgent issue in presentation of

2   COVID-19.

3

4   **Materials and Methods**

5   The study was performed following the Preferred Reporting Items for Systematic

6   reviews and Meta-Analyses guidelines (The PRISMA Statement) (**Supplementary**

7   **material**).

8

9   **Search strategy and selection criteria**

10   *Literature Search*

11   A systematic literature search of PubMed， Embase (Elsevier) and Web of Science

12   databases was performed on April 4th, 2020 (updated April 10th, 2020), using the

13   keywords "coronavirus," "severe acute respiratory syndrome coronavirus 2", "SARS-

14   CoV-2", "novel coronavirus", "nCoV," "2019-nCoV," and "COVID-19." Considering

15   the urgency of the topic and the need to increase the sensitivity of the search, a gray

16   literature search was performed using the same keywords on Google Scholar to capture

17   the most recently published articles. Furthermore, the World Health

18   Organization(WHO) database of publications, the Lancet COVID-19 Resource Centre,

19   NEJM, JAMA, BMJ, Gastroenterology, GUT, American Journal of Gastroenterology

20   and Centers for Disease Control and Prevention (CDC) COVID-19 publications were

21   screened for potentially relevant publications. Additional articles were retrieved by

9

1 screening the reference lists of included studies and from the archives of the reviewers.

2 Literature search was restricted to English language. One of the reviewers (YQ) with

3 experience in database searches designed the search strategy, which was subsequently

4 revised by other reviewers. In consideration of the date of the earliest confirmed reports

5 of COVID-19, the search was limited to 2020 with the start date of January 1st 2020.

6 Because of the large number of records identified from the gray literature, the Google

7 Scholar search was limited to titles. However, no additional limits were applied in the

8 PubMed, Embase or Web of Science search. Records were managed by EndNote X 9.0

9 software to exclude duplicates.

10

11 *Eligibility Criteria and Study Selection*

12 Eligible studies reported the epidemiological, clinical features of COVID-19, and the

13 prevalence of GI findings in infected patients. Literature were included with restriction

14 to English language. Given that pre-print papers in database such as bioRvix and

15 medRvix were not peer-reviewed, we did not include the publications in our present

16 analysis to avoid any potential misinformation being disseminated at present. The

17 following studies were excluded: (a) duplicate publications, (b) reviews, editorials, (c)

18 single case report and (d) studies pertaining to other coronavirus-related illnesses, such

19 as Middle East respiratory syndrome (MERS), and (d) small case series (<10 cases).

20 Two reviewers (YQ, JSH) independently screened the titles and abstracts according to

1   these eligibility criteria. Disagreement was discussed with other reviewers and

2   subsequently resolved via consensus.

3

4   *Risk of Bias*

5   Two reviewers (JSH, JYT) independently rated the quality of included studies using

6   the National Institutes of Health Quality Assessment Tool for Case Series Studies[13].

7   Any disagreement was resolved by the third senior reviewer (RM).

8

9   **Data extraction and definitions**

10   The two investigators (QY and JSH) who performed the literature search also

11   independently extracted the data from included studies. Disagreements were resolved

12   by a third investigator (RM) or by consensus. We extracted the following variables:

13   author, date, study design, country, patient demographics, number of participates in

14   severe and non-severe disease group, the prevalence of clinical GI symptoms such as

15   vomiting, nausea, diarrhoea, loss of appetite, abdominal pain, and belching, together

16   with digestive system comorbidities including liver disease, and gastrointestinal

17   diseases. Liver injury was defined according to the studies. Any kind of abnormal of

18   liver damage indices such as Alanine aminotransferase (ALT), Aspartate

19   aminotransferase (AST), and total bilirubin (TB) was also classified as liver injury. The

20   disease severity was defined according to the studies, mainly based on the symptoms

21   present at diagnosis, in some cases, patients with pulse oxygen saturation

1 (SpO2)<90%[14] or need of intensive care unit (ICU) care[15] or with ARDS[16] were also

2 classified as severe cases. COVID-19 was diagnosed on the basis of the WHO interim

3 guidance.[17]

4

5 **Data Synthesis and Statistical Analysis**

6 For estimate of standardised mean difference (SMD) or weighted mean differences, we

7 used 2 simple formulas proposed by Hozo et al[18] to estimate the mean using the values

8 of the median, the low and high ends of the range, and the sample size. The odds ratio

9 (OR, 95% confidence intervals (CI)) was used to describe the ratio of the probability of

10 events occurring in severe vs. non-severe patients with COVID-19. Owing to

11 heterogeneity within and between studies, a random effect model was used to estimate

12 the average effect and its precision, which would give a more conservative estimate of

13 the 95% CI. We used the I^2 statistic and Cochran's Q test to assess statistical

14 heterogeneity. A meta-analysis was planned to assess the association of GI symptoms

15 and liver injury with demographic data, outcomes, and disease characteristics. The

16 meta-analysis was performed using the metaprop command of the meta package in R

17 (version 3.2.0) for pooling single-armed rates, Stata (version 12.1) with the commands

18 metareg (for meta-regression) for assessment of publication bias, and Review Manager

19 (RevMan version 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration,

20 2014) for all the other analyses.

21 **Publication Bias**

1 Funnel-plot asymmetry as proposed by Begg and Egger et al[19] was used to investigate

2 the possibility of publication bias.

3

4 **Role of the funding source**

5 There is no funding for this study. The corresponding author had full access to all the

6 data in the study and had final responsibility for the decision to submit for publication.

7

8

1 **RESULTS**

2 **1.Study selection**

3 Among the 8,948 records that were identified through electronic and hand-search

4 strategies after removal of duplication, two reviewers (YQ and JSH) independently

5 evaluated the titles and abstracts, removed 8,896 irrelevant studies, and selected 52

6 potentially relevant reports that were identified and retrieved for detailed evaluation.

7 Two studies[20, 21] were excluded due to lack of absolute numbers for outcomes, 8

8 studies[22-29] were excluded due to case series with patients <10, and 7 studies were

9 further excluded due to being pre-print papers in database medRvix, thus 35 studies[2, 8,

10 9, 12, 14-16, 30-57], comprising 6,686 patients with COVID-19 met the inclusion criteria and

11 were included in the quantitative synthesis (**Figure 1).**

12

13 **2. Characteristics and assessment of quality of the included studies**

14 The main characteristics of patients and studies included in the meta-analysis are shown

15 in (**Appendix, Supplementary Table 1**). The majority of studies were from China,

16 except one from Singapore[31] and one from United States.[30] The studies included mainly

17 adult patients except four paediatric studies[8, 37, 43, 54] and 6 studies[2, 9, 38, 45, 46, 53] with

18 small group of paediatric patients (36 patients in total). All the included studies were

19 rated low by National Institutes of Health (NIH) Quality Assessment Tool for Case

20 Series Studies (**Appendix, Supplementary Table 2**).

21

1 **3. Gastrointestinal features**

2 *3.1 Digestive system comorbidities*

3 By combining 21 studies reporting GI data of patients with COIVD-19 at diagnosis, the

4 pooled estimate of digestive system comorbidities (i.e underlying gastrointestinal

5 disease and liver disease) rate was 4% (95% CI: 2%- 5%; range: 0–15%; I^2=74%;

6 **supplementary. Figure 1**). Specifically, the pooled estimate rate of liver disease

7 comorbidities was 3% (95% CI: 2%–4%; range: 0– 25%; I^2=57%). The most reported

8 digestive system comorbidities included chronic hepatitis or liver cirrhosis, and peptic

9 ulcer.

10

11 *3.2 Gastrointestinal symptoms as the initial presenting symptoms*

12 Gastrointestinal symptoms as the initial symptoms have been reported in several case

13 series. [40] COVID-19 induced diarrhoea at onset was first reported in a patient with

14 COVID-19, [58] and subsequently confirmed by cases in Singapore [31] and Japan[59].

15 The pooled estimate of GI symptoms as presenting symptoms was 10% (95% CI: 4%-

16 19%; range: 3%–23%; I^2= 97%; 5 studies, **supplementary Figure 2**). Patients

17 presenting with GI symptoms had longer duration from illness onset to admission

18 (SMD 2.85, 95% CI: 0.22-5.48, p=0.030, I^2=73%).

19 The result regarding detection of COVID-19 virus Ribonucleic Acid (RNA) in stool or

20 rectal swab is summarized in **Appendix, Supplementary Table 3**.[5, 8, 31, 37, 59-64] The

1   positivity rate of COVID-19 viral RNA in faecal samples was 54% (95%CI 44%-64%,

2   I^2= 28%).

3

4   *3.3 Rate of gastrointestinal symptoms*

5   GI symptoms and abnormal liver function in patients with COVID-19 from the included

6   studies are summarized in **Appendix, Supplementary Table 4.** Combining all 29

7   studies (n=6,064) reporting GI symptoms in patients with COVID-19 at diagnosis, the

8   pooled rate of digestive symptoms was 15% (95% CI: 10%- 21%; range: 2%–57%; I^2=

9   96%; **supplementary Figure 3**). Specifically, nausea and/or vomiting, diarrhoea and

10   anorexia were the main GI symptoms. The pooled estimate rate of diarrhoea was 9%

11   (95% CI: 6%- 12%; range: 1%– 34%; I^2=89%; 26 studies(n=), **Figure 2a**).The pooled

12   estimate of nausea and/or vomiting rates were 7% (95% CI: 5%- 9%; range: 1%–22%;

13   I^2=88%; 18 studies(n=)), loss of appetite was 21% (95% CI: 9%–44%; range: 1%– 79%;

14   I^2=98%; 8 studies (n=), and abdominal pain was 3% (95% CI: 2%–5%; range: 1%– 4%;

15   I^2=31%; 6 studies(n=)), respectively **(Figure 2b-d)**.

16

17   *3.4 Liver injury*

18   Regarding presence of liver injury, the pooled estimate of 12 studies (n=1,267) was 19%

19   (95% CI: 9%-32%; range: 1%-53%; I^2= 96%; **supplementary Figure 4**). More

20   specifically, the pooled estimate of the rate of elevated ALT was 18% (95% CI: 13%–

21   25%; range: 4%–40%; I^2= 90%), elevated AST was 21% (95% CI: 14%–29%; range:

1 4%–53%; I^2= 92%), and elevated TB was 8% (95% CI: 3%–18%; range: 1%–31%; I^2=

2 94%; **Figure 3a-c**). The pooled estimate of the rate of decreased ALB (albumin) was

3 32% (95% CI: 3%–89%; range: 6%–78%; I^2=98%; **Figure 3d**).

4

5 *3.5The clinical course of patients with GI symptoms*

6 The proportion of severe/critical cases was markedly increased in COVID-19 patients

7 with GI symptoms compared with those without GI symptoms (31.6% vs.13.4%, OR

8 3.97, 95% CI: 1.49-10.62, p=0.0060, I^2=79%, **Figure 4**). However, the risk of severe

9 disease was not increased among patients with digestive/liver-related comorbidities

10 (OR 0.57, 95% CI:0.15, 2.18, p=0.41, I^2=44%) when compared with patients without

11 these comorbidities (supp. **Figure** 5).

12 Patients with GI symptoms had a higher risk of ARDS (OR 2.96, 95% CI: 1.17- 7.48,

13 p=0.020) and liver injury (OR 2.71, 95% CI: 1.52-4.83, p<0.01) (**supp. Figure 6**).

14 However, the pooled rate of discharge (OR 0.72, 95% CI: 0.37-1.41, p=0.34, n=458,

15 **Figure 4**) , the length of hospital stay (SMD 1.70, 95% CI: -0.81, 4.21, P=0.18, n=341)

16 and the rates of death (OR 1.21, 95% CI: 0.68-2.16, p =0.52, I^2=8%, **Figure 4**) were

17 comparable between patients with and without GI symptoms.

18

19 **4. Subgroup analysis**

20 *4.1 Severe Vs non-severe COVID-19*

We analysed the difference in GI symptoms between severe and non-severe patients

with COVID-19 (Figure 5). Patients with severe cases were more likely to present with

GI symptoms compared to non-severe ones (OR 1.61, 95% CI: 1.09, 2.36, p=0.020,

I^2=44%). More specifically, a higher risk of patients presenting with abdominal pain

(OR 7.15, 95% CI: 1.95, 26.27; p=0.0030, I^2=0) was observed in the severe group

compared to those in non-severe patients. However, there were no statistically

significant difference between severe and non-severe patients in loss of appetite (OR

2.83, 95% CI: 0.92, 8.69, p=0.070, I^2=64%), diarrhoea (OR 1.22, 95% CI: 0.81-1.84;

p=0.35, I^2=0) , or nausea and/or vomiting (OR 1.23, 95% CI: 0.69-2.19; p=0.49,

I^2=32%).

A higher risk of liver injury was observed in the severe group compared to those in non-

severe group with an OR of 2.2 (95% CI: 1.60-3.02, p<0.001, I^2=36%, **Figure 6**). The

value of liver damage indices such as ALT (standardized mean difference(SMD), 0.46;

95% CI, 0.27 to 0.65; P < 0.001) and AST (SMD, 0.36; 95% CI, 0.12 to 0.60; P =

0.0030) and TB (SMD, 0.28; 95% CI, 0.02 to 0.54; P = 0.030) levels were significantly

elevated in patients with severe group compared with non-severe group

(**Supplementary. Figure 7**). However, the pooled analysis failed to demonstrate a

significant difference in albumin (ALB) levels between two groups (SMD,- 0.23; 95%

CI, -0.51 to 0.06; P =0 .11; **Supplementary. Figure 7**).

4.2 Patients in Hubei vs. outside Hubei

1   We further analysed the differences between patients in Hubei (the place of COVID-19

2   initial outbreak in China, n=4,009) vs. outside Hubei province (n=2,677). The incidence

3   of overall GI symptoms at diagnosis (17%[95%CI 10-28%] vs. 9%[95%CI 6-14%]; p=

4   0.078) were comparable between the two groups. There was a higher proportion of

5   patients in Hubei presenting with nausea and/or vomiting(8%[95%CI 5-11%] vs.

6   4%[95%CI 3-7%]; P=0.045) compared to those outside Hubei (**Appendix,**

7   **Supplementary Table 5**). Other symptoms including diarrhoea and loss of appetite

8   were comparable between patients in Hubei and outside Hubei.

9   However, there is a higher risk of liver injury in patients of Hubei compared to those

10   outside Hubei (21% [95%CI 4-59%] vs. 10% [95%CI 4-25%]; P<0.01).This trend is

11   further confirmed by the data that a larger proportion of patients in Hubei had elevated

12   ALT (25% [95%CI 17-35%] vs. 15% [95%CI 9-23%]; P=0.069) , AST (30% [95%CI

13   18-46%] vs. 16% [95%CI 11-24%]; P=0.053) and TB (24% [95%CI 16-33%] vs. 4%

14   [95%CI 2-9%]; P<0.001) compared to cases outside Hubei (**Appendix,**

15   **Supplementary Table 5**).

16

17   **4.3 Adult vs Paediatric patients**

18   We further analysed whether digestive symptoms varied between adult (n=6420) and

19   paediatric patients (n=266). GI symptoms including diarrhoea (9%[95%CI 6-13%] vs.

20   10%[95%CI 6-15%], p=0.78), and nausea and/or vomiting(7% [95%CI 5-9%] vs. 6%

21   [95%CI 4-11%]; P=0.95) were comparable between the two groups (**Appendix,**

1 **Supplementary Table 5**). Similarly, paediatric patients with COVID-19 had an

2 equivalent risk of liver injury (10% [95%CI 4-22%] vs. 18% [95%CI 8-35%]; P= 0.32),

3 as compared with adult cases. However, paediatric patients were less likely to present

4 with elevated ALT compared with adult patients (7% [95%CI 3-18%]; P=0.034 vs. 20%

5 [95%CI 14-28%]) (**Appendix, Supplementary Table 5**).

6

7 **5. Publication bias**

8 Significant publication bias was found either by funnel plot or by the Egger test (p

9 <0.01) for GI symptoms (**supplementary. Figure 8**) but not for liver injury (p= 0.18).

10

11

1 **Discussion**

2 An increasing number of studies reported the involvement of the digestive system in

3 patients with COVID-19. The present study aimed to investigate the pooled rate of GI

4 symptoms and liver injury in COVID-19. Overall, the pooled rates of GI symptom and

5 liver injury were 15% and 19% in patients with COVID-19, respectively. As the

6 severity of the disease increases, digestive symptoms and liver injury become more

7 pronounced. About 10% patients presented with GI symptoms alone without

8 respiratory features. Patients with GI system involvement tend to have delayed

9 diagnosis, higher risk of severe/critical disease and development of ARDS.

10

11 Over the course of the current pandemic, some patients can initially present with

12 abdominal symptoms even without fever or respiratory manifestations[58]. In a large

13 multicentre study,[12] of 204 patients with COVID-19 in three heavily affected hospitals

14 during the initial outbreak in China, 99 patients (48.5%) presented with digestive

15 symptoms as their chief complaint. There were 7 cases presenting with digestive

16 symptoms but no respiratory symptoms. Luo[40] reported a large case series (n=1,141) of

17 hospitalised patients with SARS-CoV-2 infection, 183 (16%) presented with

18 gastrointestinal symptoms only. Wang et al [33] also found around one in ten (10.1%)

19 patients initially presented with diarrhoea and nausea 1 to 2 days prior to development

20 of fever and dyspnoea. In the present study, about 10% (95% CI: 4%- 19%; range: 3%–

21 23%; $I^2 = 97\%$) patients presented with GI symptoms alone without respiratory features.

1

2   Patients with digestive symptoms had a variety of manifestations, such as loss of

3   appetite (83 (83.8%) cases), diarrhoea (29 (29.3%) cases), vomiting (8 (0.8%) cases),

4   and abdominal pain (4 (0.4%) cases). [12]According to the present study, 15% (95% CI:

5   10%- 21%) patients with COVID-19 presented with digestive symptoms, including

6   nausea and/or vomiting with a pooled rate of 7% (95% CI: 5%- 9%), diarrhoea 9% (95%

7   CI: 6–12%), loss of appetite 21% (95% CI: 9–44%), and abdominal pain 4% (95% CI:

8   3–4%). Autopsy studies are important to help investigate the histopathological change

9   of GI tract in COVID-19. Currently there is only one published autopsy report in an 85-

10   year-old man with COVID-19, which showed segmental dilatation and stenosis in the

11   small intestine.[64] Further studies are needed to clarify whether this finding is secondary

12   to COVID-19 or a pre-existing GI comorbidity.

13   In addition to digestive symptoms, patients with COVID-19 are also at risk of

14   developing liver injury. Recent studies have shown that patients had varying degrees of

15   liver function abnormalities, the incidence ranged from 14.8% to 53%, mainly indicated

16   by abnormal ALT and AST levels, accompanied by slightly elevated bilirubin levels.

17   The albumin was decreased in severe cases and the level of albumin was around 26.3-

18   30.9 g/L.[32] In our study, the pooled estimate of liver injury was 19% (95% CI: 9%-

19   32%). Our findings indicate that one in five patients will develop liver function

20   abnormalities, especially in severe cases (may be as high as 53%), thus special notice

1 of liver dysfunction should be taken in treating COVID-19 patients over the

2 hospitalisation period.

3 The characteristics of the liver injury was slight elevation in hepatocyte related enzymes

4 including ALT and AST. Cholangiocyte related enzymes such as alkaline

5 phosphatase (ALP) and γ-glutamyl transpeptidase (GGT) were also reported to be

6 slightly elevated in a few patients (3.1% and 3.0%).[65] Studies on the exact mechanism

7 of COVID-19 related liver injury are scarce. Liver abnormalities of COVID-19 patients

8 may be due to viral infection in liver cells or other causes such as drug toxicity and

9 systemic inflammation [66]. A recent postmortem biopsy study in a COVID-19 patient

10 showed moderate microvascular steatosis and mild lobular and portal activity,

11 indicating the injury could have been caused by either COVID-19 infection or drug-

12 induced liver injury.[67 68] Similar to the situation in SARS, drugs such as antivirals might

13 potentially cause liver injury in COVID-19. [69] However, one study reported that there

14 was no statistical difference between patients on medication or not when stratified by

15 the prehospital medications including antibacterial drugs, antiviral drugs (abidol,

16 oseltamivir, acyclovir), and antipyretic drugs with paracetamol (acetaminophen).[68]

17 Further studies are warranted in this setting.

18 The link between GI involvement and disease severity of COVID-19 has been proposed

19 recently. In a multicentre study, Lei et al. [12]investigated the prevalence and outcomes

20 of COVID-19 patients with digestive symptoms. In 99 patients who presented with

21 digestive symptoms as chief complaint, a longer time from onset to admission was

observed compared to patients without digestive symptoms (9.0 days vs. 7.3 days). As the severity of the disease increased, digestive symptoms became more pronounced. Patients without digestive symptoms were more likely to be cured and discharged than patients with digestive symptoms (60% vs. 34.3%).[12] This was consistent with the study from Wang et al who found that patients admitted to the ICU were more likely to have abdominal pain and loss of appetite compared with the non-ICU patients.[33] In the present study, we performed subgroup analysis to investigate the difference in GI symptoms between severe and non-severe patients with COVID-19. Indeed, there was a higher prevalence of GI symptoms (OR 1.61, 95% CI: 1.09-2.36, p=0.020), including anorexia (OR 2.83, 95% CI: 0.92-8.691, p=0.070), and abdominal pain (OR 7.15, 95% CI: 1.95-26.27; p=0.0030) in the severe group compared to the non-severe cases. Cai et al [65] showed liver injury occurred more frequently in severe patients (36.2% vs. 9.6%, p<0.001) than non-severe patients. We also found a significantly higher risk of liver function abnormalities in the severe group compared to those in non-severe group(OR 2.2, 95% CI: 1.60-3.02, p<0.001). In COVID-19 cases who died, the incidence of liver injury might reach as high as 58.06% [70] and 78% [71]. One study reported that serum ALT and AST levels increased up to 7590 U/L and 1445 U/L respectively in a severe COVID-19 patient.[32]

In the present study, we further investigated the disease course and outcomes in subgroups of patients with digestive system involvement. We found patients presenting with initial GI symptoms had longer duration from illness onset to admission (SMD

1 2.85, 95% CI: 0.22-5.48, p=0.030), and the rate of the severe/critical type was markedly

2 increased when compared to those without GI symptoms (31.6% vs.13.4%, OR 3.97,

3 95% CI: 1.49-10.62, p=0.0060). Patients with GI symptoms also had a higher risk of

4 ARDS (OR 2.96, 95% CI: 1.17- 7.48, p=0.020). No significant difference was seen

5 when considering pooled rates of discharge (OR 0.72, 95% CI: 0.37-1.41, p=0.34),

6 length of hospital stay (SMD 1.70, 95% CI: -0.81, 4.21, P=0.18) and rates of death (OR

7 1.21, 95% CI: 0.68-2.16, p =0.52) between patients with and without GI symptoms.

8 This may be due to the relatively low incidence of each event. Moreover, the risk of

9 severe case was not increased among COVID-19 patients with existing digestive/liver-

10 related comorbidity when compared with patients without such comorbidity (OR 0.57,

11 95% CI:0.15, 2.18, p=0.41). Thus, the newly presenting GI symptoms rather the

12 existing digestive/liver-related comorbidity were predictive of severe disease course.

13 Altogether, our findings supported the importance of including symptoms like

14 diarrhoea to diagnose COVID-19 early.

15

16 The characteristics of patients with imported COVID-19 outside Hubei may vary from

17 patients in Hubei. An early study including 80 imported cases of COVID-19 in Jiangsu

18 Province showed that imported cases exhibited mild or moderate symptoms and lower

19 proportion of liver dysfunction compared with the cases in Wuhan.[38] Our subgroup

20 analysis suggested that there was no difference in rate of overall GI symptoms. Patients

21 in Hubei had a higher risk of presenting with abnormal liver function. It might be argued

1   that there were more severe cases in Hubei compared with those outside Hubei, which

2   may result in the higher percentage of patients with abnormal liver function in Hubei.

3   However, our present analysis included studies that did not show significant difference

4   in percentage of severe cases between Hubei and outside Hubei (data not shown). This

5   needs to be further investigated in future studies.

6

7   A few paediatric cases are reported and their clinical features have yet to be fully

8   evaluated. In a recent landmark clinical investigation on ten paediatric COVID-19 cases

9   in China, these patients had clinically milder symptoms and showed fewer alterations

10   in radiological and laboratory testing parameters.[8] In the present study, we included 4

11   paediatric studies with 227 patients in total.[8, 37, 43, 54] According to our subgroup analysis,

12   paediatric patients with COVID-19 had a lower risk of elevated ALT, as compared with

13   adult cases. However, the GI symptoms including diarrhoea, and nausea or vomiting

14   were comparable between paediatric and adult patients.

15

16   Emerging data showed the prolonged presence of COVID-19 virus RNA in stool

17   samples or rectal swab even after the patients' respiratory specimens were negative.[8, 61]

18   Much attention has been paid to the possibility of virus shedding by gastrointestinal tract

19   and faecal–oral transmission. In the clinical investigation on ten paediatric COVID-19

20   cases, eight persistently tested positive on rectal swabs even after nasopharyngeal testing

21   was negative. [8] After reviewing all studies testing virus RNA in stool or rectal swabs,

1   the positive rate of COVID-19 viral RNA in faecal samples was 54% (95%CI 44%-

2   64%), the duration of virus positivity can persist for as long as 47 days after symptom

3   onset (**Appendix, supplementary Table 3**). Data from Wu et al [61] suggest the possibility

4   of extended duration of viral shedding in faeces, for nearly 5 weeks after the patients'

5   respiratory samples tested negative for COVID-19. However, the clinical implication of

6   prolonged faecal virus excretion including its association with disease course, severity

7   and even recurrence of COVID-19 remains unclarified. It clearly may have major public

8   health and clinical policy significance. More studies are needed to demonstrate its

9   replication-competence, its abundance in stool and stability in environment[72-73].

10

11 This meta-analysis is potentially limited in several ways. First, an assessment of the

12 methodological quality determined that there were deficiencies in studies evaluated, as

13 all the 35 studies included were considered low-quality. Second, due to lack of

14 sufficient data reported in the original publications, it was not possible to evaluate the

15 effect of other factors, such as gender, age, and comorbidities, on the rate of

16 gastrointestinal symptoms at diagnosis, and risk of liver injury. Third, the criteria for

17 severe COVID-19 differed among studies, which may contribute to the heterogeneity

18 of the meta-analysis. As defined in the methods section, we took the criteria per study,

19 in other cases we defined the severe cases by their symptoms (SpO2<90% or ARDS)

20 or poor prognosis (need of ICU care). Last but not the least, significant heterogeneity

21 and publication bias were observed in our study for estimating the prevalence of

digestive system symptoms. After reviewing each study, the majority of heterogeneity were from nonspecific symptom of appetite loss, and two studies [40, 49] focusing on patients with GI symptoms. When these studies were excluded from the analysis, the pooled rate of digestive symptoms was 7% (95% CI: 5% - 8%; I^2 = 78%), which is of modest heterogeneity. The pooled rate is lower than 15% due to the high incidence of loss of appetite. However, the pooled rates of other three symptoms were similar to original results with only mild or modest heterogeneity.

In conclusion, the present systematic review and meta-analysis suggest that the digestive symptoms and liver injury are not uncommon in patients with COVID-19. Compared with non-severe cases, severe cases with COVID-19 had a higher risk of developing GI symptoms and liver injury. Patients in Hubei had comparable risk of developing GI symptoms but higher risk of liver injury than those outside Hubei. Paediatric patients with COVID-19 have equivalent risk of GI symptoms compared with adult patients. One tenth of patients with COVID-19 may present only with GI symptoms without respiratory symptoms. Patients with GI system involvement have delayed diagnosis with a tendency to severe/critical type and a poor disease course. More attention should be paid to the care of these unique group of patients.

References

1. Coronavirus disease 2019 (COVID-19) Situation Report – 74. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200403-sitrep-74-covid-19-mp.pdf?sfvrsn=4e043d03_14. Accessed April 12, 2020.

2. WJ Guan, Z Ni,Y Hu, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020. DOI: 10.1056/NEJMoa2002032

3. F Xiao, M Tang, X Zheng, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020. DOI: 10.1053/j.gastro.2020.02.055.

4. F Qi, S Qian, S Zhang, et al. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochemical and biophysical research communications 2020. DOI: 10.1016/j.bbrc.2020.03.044.

5. ML Holshue, C DeBolt, S Lindquist, et al. First Case of 2019 Novel Coronavirus in the United States. New England Journal of Medicine 2020;382:929-936. DOI: 10.1056/NEJMoa2001191

6. R Wölfel, VM Corman, W Guggemos, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020. DOI: 10.1038/s41586-020-2196-x

7. X Yao, T Li, Z He, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Chinese journal of pathology 2020;49:E009. DOI: 10.3760/cma.j.cn112151-20200312-00193

8. Y Xu, X Li, B Zhu, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nature Medicine 2020. DOI: 10.1038/s41591-020-0817-4

9. D Chang M Lin, L Wei, et al. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. JAMA 2020. DOI: 10.1001/jama.2020.1623

10. L Wang, Y Gao, L Lou, et al. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. The European respiratory journal 2020. DOI: 10.1183/13993003.00398-2020

11. X Jin, J Lian, J Hu, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020. DOI: 10.1136/gutjnl-2020-320926

12. L Pan M Mu, H Ren, et al.. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study American journal of gastroenterology 2020. DOI : 10.14309/ajg.0000000000000620

13. National Heart, Lung, and Blood Institute website. Study quality assessment tools. www.nhlbi.nih. gov/health-topics/study-quality-assessment-tools. Accessed February 16, 2020

14. Z Wang, B Yang, Q Li, et al. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020. DOI: 10.1093/cid/ciaa272

15. C Huang, Y Wang, X Li, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 2020;395:497-506. DOI: 10.1016/S0140-6736(20)30183-5

16. C Wu, X Chen, Y Cai, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA internal medicine 2020. DOI: 10.1001/jamainternmed.2020.0994

17. Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance. Accessed April 12, 2020.

18. SP Hozo, B Djulbegovic, I Hozo. Estimating the mean and variance from the median, range, and the size of a sample. BMC medical research methodology 2005;5:13. DOI: 10.1186/1471-2288-5-13

19. M Egger, G Smith, M Schneider, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed.) 1997;315:629-34. DOI: 10.1136/bmj.315.7109.629

20. Q Li, X Guan, P Wu, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. New England Journal of Medicine 2020;382:1199-1207. DOI: 10.1056/NEJMoa2001316

21. Y Pan, D Zhang, P Yang, et al. Viral load of SARS-CoV-2 in clinical samples. The Lancet. Infectious diseases 2020;20:411-412. DOI: 10.1016/S1473-3099(20)30113-4

22. Q Chen, B Quan, X Li, et al. A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019. Journal of Medical Virology 2020. DOI: 10.1002/jmv.25755

23. JF Chan, S Yuan, K Kok, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet (London, England) 2020;395:514-523. DOI: 10.1016/S0140-6736(20)30154-9

24. Z Wang, X Chen, Y Lu, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Bioscience trends 2020;14:64-68. DOI: 10.5582/bst.2020.01030

25. Z Zhang, X Li, W Zhang, et al. Clinical Features and Treatment of 2019-nCov Pneumonia Patients in Wuhan: Report of A Couple Cases. Virologica Sinica 2020. DOI: 10.1007/s12250-020-00203-8

26. F Lescure, L Bouadma, D Nguyen, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. The Lancet. Infectious diseases 2020. DOI: 10.1016/S1473-3099(20)30200-0

27. C Luo, L Yao, L Zhang, et al. Possible Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Public Bath Center in Huai'an, Jiangsu Province, China. JAMA network open 2020;3:e204583. DOI: 10.1001/jamanetworkopen.2020.4583

28. N Yu, W Li, Q Kang, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. The Lancet. Infectious diseases 2020. DOI: 10.1016/S1473-3099(20)30176-6

29. L Zeng, S Xia, W Yuan, et al. Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China. JAMA pediatrics 2020. DOI: 10.1001/jamapediatrics.2020.0878

30. M Arentz, E Yim, L Klaff, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA 2020. DOI: 10.1001/jama.2020.4326

31. BE Young, S Ong, S Kalimuddin, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA 2020. DOI: 10.1001/jama.2020.3204

32. N Chen, M Zhou, X Dong, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020;395:507-513. DOI: 10.1016/S0140-6736(20)30211-7

33. D Wang, B Hu, C Hu, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020. DOI: 10.1001/jama.2020.1585

1 34. F Song, N Shi, F Shan, et al. Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia.

2   Radiology 2020;295:210-217. DOI: 10.1148/radiol.2020200274

3 35. F Zhou, T Yu, R Du, et al. Clinical course and risk factors for mortality of adult inpatients with

4   COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England) 2020. DOI:

5   10.1016/S0140-6736(20)30566-3

6 36. H Shi, X Han, N Jiang, et al. Radiological findings from 81 patients with COVID-19 pneumonia

7   in Wuhan, China: a descriptive study. The Lancet. Infectious diseases 2020. DOI:

8   10.1016/S1473-3099(20)30086-4

9 37. J Cai, J Xu, D Lin, et al. A Case Series of children with 2019 novel coronavirus infection: clinical

10   and epidemiological features. Clinical infectious diseases : an official publication of the

11   Infectious Diseases Society of America 2020. DOI: 10.1093/cid/ciaa198

12 38. J Wu, J Liu, X Zhao, et al. Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu

13   Province: A Multicenter Descriptive Study. Clinical infectious diseases : an official publication

14   of the Infectious Diseases Society of America 2020. DOI: 10.1093/cid/ciaa199

15 39. K Liu, Y Fang, Y Deng, et al. Clinical characteristics of novel coronavirus cases in tertiary

16   hospitals in Hubei Province. Chinese medical journal 2020. DOI:

17   10.1097/CM9.0000000000000744

18 40. S Luo, X Zhang, H Xu. Don't overlook digestive symptoms in patients with 2019 novel

19   coronavirus disease (COVID-19). Clinical Gastroenterology and Hepatology 2020. DOI:

20   10.1016/j.cgh.2020.03.043

41. M Ng, E Lee, J Yang, et al. Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review. Radiology: Cardiothoracic Imaging 2020;2:e200034. DOI: 10.1148/ryct.2020200034

42. W Yang, Q Cao, L Qin, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. The Journal of infection 2020. DOI: 10.1016/j.jinf.2020.02.016

43. X Lu, L Zhang, H Du, et al. SARS-CoV-2 Infection in Children. The New England journal of medicine 2020. DOI: 10.1056/NEJMc2005073

44. X Xu, C Yu, J Qu, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. European journal of nuclear medicine and molecular imaging 2020. DOI: 10.1007/s00259-020-04735-9

45. X Xu, X Wu, X Jiang, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606. DOI: 10.1136/bmj.m606

46. Y Liu, Y Yang, C Zhang, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China. Life sciences 2020;63:364-374. DOI: 10.1007/s11427-020-1643-8

47. Z Zhou, N Zhao, Y Shu, et al. Effect of gastrointestinal symptoms on patients infected with COVID-19. Gastroenterology 2020. DOI: 10.1053/j.gastro.2020.03.020

48. J Zhang, X Dong, Y Cao, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020. DOI: 10.1111/all.14238

49. C Han, C Duan, S Zhang, et al. Digestive Symptoms in COVID-19 Patients with Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes American journal of gastroenterology 2020.

50. B Cao, Y Wang, D Wen, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. The New England journal of medicine 2020. DOI: 10.1056/NEJMoa2001282

51. W Guo, M Li, Y Dong, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes/metabolism research and reviews 2020:e3319. DOI: 10.1002/dmrr.3319

52. X Jin, J Lian, J Hu, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020. DOI: 10.1136/gutjnl-2020-320926

53. M Du, G Cai, F Chen, et al. Multi-omics Evaluation of Gastrointestinal and Other Clinical Characteristics of SARS-CoV-2 and COVID-19. Gastroenterology 2020.

54. H Qiu, J Wu, L Hong, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. The Lancet. Infectious diseases 2020. DOI: 10.1016/S1473-3099(20)30198-5

55. S Shi, M Qin, B Shen, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA cardiology 2020. DOI: 10.1001/jamacardio.2020.0950

56. P Wu, F Duan, C Luo, et al. Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA ophthalmology 2020. DOI: 10.1001/jamaophthalmol.2020.1291

57. M Zheng, Y Gao, G Wang, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cellular & molecular immunology 2020. DOI: 10.1038/s41423-020-0402-2

58. Y Song, P Liu, X Shi, et al. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut 2020. DOI: 10.1136/gutjnl-2020-320891

59. FF Guglielmo, SA Anupindi, JG Fletcher, et al. Small Bowel Crohn Disease at CT and MR Enterography: Imaging Atlas and Glossary of Terms. Radiographics 2020:190091. DOI: 10.1148/rg.2020190091

60. I Ghinai, TD McPherson, JC Hunter, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. The Lancet. DOI: 10.1016/S0140-6736(20)30607-3

61. Y Wu, C Guo, L Tang, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. The lancet. Gastroenterology & hepatology 2020. DOI: 10.1016/S2468-1253(20)30083-2

62. A Carvalho, R Alqusairi, A Adams, et al. SARS-CoV-2 Gastrointestinal Infection Causing Hemorrhagic Colitis: Implications for Detection and Transmission of COVID-19 Disease. American journal of gastroenterology 2020.

63. C Chen, G Gao, Y Xu, et al. SARS-CoV-2-Positive Sputum and Feces After Conversion of Pharyngeal Samples in Patients With COVID-19. Annals of internal medicine 2020. DOI: 10.7326/M20-0991

64. T Hosoda, M Sakamoto, H Shimizu, et al. SARS-CoV-2 enterocolitis with persisting to excrete the virus for about two weeks after recovering from diarrhea: A case report. Infection control and hospital epidemiology 2020:1-4. DOI: 10.1017/ice.2020.87

65. Q Liu, R Wang, G Qu, et al. Macroscopic autopsy findings in a patient with COVID-19. Journal of Forensic Medicine (in Chinese) 2020;36:1-3.

66. Q Cai, D Huang, P Ou, et al. COVID-19 in a Designated Infectious Diseases HospitalOutside Hubei Province,China. medRxiv 2020. DOI: 10.1101/2020.02.17.20024018

67. X Chai, L Hu, Y Zhang, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv 2020. DOI: 10.1101/2020.02.03.931766

68. Z Xu, L Shi, Y Wang, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet. Respiratory medicine 2020. DOI: 10.1016/S2213-2600(20)30076-X

69. Z Fan, L Chen, J Li, et al. Clinical Features of COVID-19 Related Liver Damage. medRxiv 2020. DOI: 10.1101/2020.02.26.20026971

70. X Yang, Y Yu, J Xu, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet. Respiratory medicine 2020. DOI: 10.1016/S2213-2600(20)30079-5

71. Y Huang, R Yang, Y Xu, et al. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. medRxiv 2020. DOI: 10.1101/2020.02.27.20029009

72. B Zhang, X Zhou, Y Qiu, et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv 2020. DOI: 10.1101/2020.02.26.20028191

73. N van Doremalen, T Bushmaker, DH Morris, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. The New England journal of medicine 2020. DOI: 10.1056/NEJMc2004973

1   74.   C Yeo, S Kaushal, D Yeo. Enteric involvement of coronaviruses: is faecal-oral transmission of

2   SARS-CoV-2 possible? The lancet. Gastroenterology & hepatology 2020;5:335-337. DOI:

3   10.1016/S2468-1253(20)30048-0

Figure Legends

Figure 1. Study selection

Figure 2. Pooled estimate of GI symptoms spectrum: (a) nausea and/or vomiting, (b) diarrhoea, (c) loss of appetite and (d) abdominal pain in patients with COVID-19.

Figure 3. Estimated incidence of abnormal liver chemistry including (a) elevated ALT, (b) elevated AST, (c) elevated TB, and (d) decreased ALB in patients with COVID-19.

Figure 4. Prognosis of patients with COVID-19: Estimated incidence of (a) severe case, (b) discharge and (c) mortality, stratified by digestive system involvement

Figure 5. Forrest plot of meta-analysis of GI symptoms according to patients' disease severity (severe vs. non-severe).

Figure 6. Forrest plot of meta-analysis of odds ratio of liver chemistry according to patients' disease severity (severe vs. non-severe).